Investors Asset Management of Georgia Inc. GA ADV Buys 664 Shares of Pfizer Inc. $PFE

Investors Asset Management of Georgia Inc. GA ADV increased its stake in Pfizer Inc. (NYSE:PFE) by 0.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,272 shares of the biopharmaceutical company’s stock after purchasing an additional 664 shares during the quarter. Pfizer makes up approximately 1.1% of Investors Asset Management of Georgia Inc. GA ADV’s portfolio, making the stock its 23rd biggest holding. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Pfizer were worth $2,309,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at about $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the first quarter valued at about $28,000. North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. WPG Advisers LLC purchased a new position in Pfizer during the first quarter valued at $35,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer during the first quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Finally, Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Trading Up 1.1%

NYSE PFE opened at $27.37 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $24.67 and a two-hundred day simple moving average of $24.12. The stock has a market cap of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.